Brii Biosciences Limited 2137.HK Stock
Brii Biosciences Limited Price Chart
Brii Biosciences Limited 2137.HK Financial and Trading Overview
| Brii Biosciences Limited stock price | 0.93 HKD |
| Previous Close | 3.97 HKD |
| Open | 3.95 HKD |
| Bid | 4.11 HKD x N/A |
| Ask | 4.13 HKD x N/A |
| Day's Range | 3.94 - 4.2 HKD |
| 52 Week Range | 3.5 - 15.28 HKD |
| Volume | 20.33M HKD |
| Avg. Volume | 6.78M HKD |
| Market Cap | 3.01B HKD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.26 HKD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 HKD |
2137.HK Valuation Measures
| Enterprise Value | -134849296 HKD |
| Trailing P/E | N/A |
| Forward P/E | -4.4891305 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 24.574986 |
| Price/Book (mrq) | 0.940132 |
| Enterprise Value/Revenue | -1.103 |
| Enterprise Value/EBITDA | 0.267 |
Trading Information
Brii Biosciences Limited Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -51.28% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.28 HKD |
| 52 Week Low | 3.5 HKD |
| 50-Day Moving Average | 4.05 HKD |
| 200-Day Moving Average | 6.46 HKD |
2137.HK Share Statistics
| Avg. Volume (3 month) | 6.78M HKD |
| Avg. Daily Volume (10-Days) | 5.46M HKD |
| Shares Outstanding | 727.6M |
| Float | 530.5M |
| Short Ratio | N/A |
| % Held by Insiders | 5.41% |
| % Held by Institutions | 46.84% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -420.22% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -9.17% |
| Return on Equity (ttm) | -15.14% |
Income Statement
| Revenue (ttm) | 122.28M HKD |
| Revenue Per Share (ttm) | 0.17 HKD |
| Quarterly Revenue Growth (yoy) | 101.29% |
| Gross Profit (ttm) | N/A |
| EBITDA | -505900992 HKD |
| Net Income Avi to Common (ttm) | -484312000 HKD |
| Diluted EPS (ttm) | -0.81 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3B HKD |
| Total Cash Per Share (mrq) | 4.12 HKD |
| Total Debt (mrq) | 12.66M HKD |
| Total Debt/Equity (mrq) | 0.4 HKD |
| Current Ratio (mrq) | 13.43 |
| Book Value Per Share (mrq) | 4.393 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -496279008 HKD |
| Levered Free Cash Flow (ttm) | -438462016 HKD |
Profile of Brii Biosciences Limited
| Country | Hong Kong |
| State | N/A |
| City | Beijing |
| Address | Building 7, International Science Park |
| ZIP | 100192 |
| Phone | N/A |
| Website | https://www.briibio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 146 |
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. The company was incorporated in 2017 and is headquartered in Beijing, China.
Q&A For Brii Biosciences Limited Stock
What is a current 2137.HK stock price?
Brii Biosciences Limited 2137.HK stock price today per share is 0.93 HKD.
How to purchase Brii Biosciences Limited stock?
You can buy 2137.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Brii Biosciences Limited?
The stock symbol or ticker of Brii Biosciences Limited is 2137.HK.
Which industry does the Brii Biosciences Limited company belong to?
The Brii Biosciences Limited industry is Biotechnology.
How many shares does Brii Biosciences Limited have in circulation?
The max supply of Brii Biosciences Limited shares is 728.83M.
What is Brii Biosciences Limited Price to Earnings Ratio (PE Ratio)?
Brii Biosciences Limited PE Ratio is now.
What was Brii Biosciences Limited earnings per share over the trailing 12 months (TTM)?
Brii Biosciences Limited EPS is -0.26 HKD over the trailing 12 months.
Which sector does the Brii Biosciences Limited company belong to?
The Brii Biosciences Limited sector is Healthcare.
Brii Biosciences Limited 2137.HK included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}